Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
|ClinicalTrials.gov Identifier: NCT00314912|
Recruitment Status : Unknown
Verified July 2007 by Bellus Health Inc.
Recruitment status was: Active, not recruiting
First Posted : April 17, 2006
Last Update Posted : July 16, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Tramiprosate (3APS)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease|
|Study Start Date :||May 2006|
- To evaluate the long-term safety of Tramiprosate (3APS).
- To provide additional long-term data on the efficacy of Tramiprosate (3APS).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314912
|United States, California|
|San Francisco Clinical Research Center|
|San Francisco, California, United States|